Revance Therapeutics Inc.’s phase III trial of DaxibotulinumtoxinA Topical Gel to treat patients with moderate to severe lateral canthal lines, or crow’s feet, dubbed REALISE 1, has failed to achieve its co-primary and other endpoints.
Forex – financial instrument.Forex news
Revance Therapeutics Inc.’s phase III trial of DaxibotulinumtoxinA Topical Gel to treat patients with moderate to severe lateral canthal lines, or crow’s feet, dubbed REALISE 1, has failed to achieve its co-primary and other endpoints.